Evidence map›Paper›PMID 23071679›Full record

ArticlePloS one2012

Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile.

Gregory L Peterfreund, Lee E Vandivier, Rohini Sinha, Andre J Marozsan, William C Olson, Jun Zhu, Frederic D Bushman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 92 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Gregory L PeterfreundDepartment of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States of America.
Lee E Vandivier
Rohini Sinha
Andre J Marozsan
William C Olson
Jun Zhu
Frederic D Bushman
University of Pennsylvania · USProgenics Pharmaceuticals (United States) · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007170 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI BRASS, LAWRENCE F · 1985 to 2022
$54.0M
Training in Emerging Infectious DiseasesT32AI055400 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CHERRY, SARA, HENSLEY, SCOTT ERIC · 2003 to 2022
$4.4M
Diet, Genetic Factors, and the Gut Microbiome in Crohn's DiseaseUH2DK083981 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI BUSHMAN, FREDERIC D, LEWIS, JAMES D · 2009 to 2010
$2.3M
PA-50/PA-41 antitoxin antibody therapy for C. difficile infectionR01AI094424 · NIAID · PROGENICS PHARMACEUTICALS, INC. · PI OLSON, WILLIAM C · 2011 to 2012
$2.3M
NIAID NIH HHS R01 AI 094424NIAID NIH HHS R01 AI094424NIAID NIH HHS T32 AI055400NIDDK NIH HHS UH2 DK083981NIDDK NIH HHS UH2DK083981NIGMS NIH HHS T32 GM007170
6 · The paper itself

Abstract

Antibiotic disruption of the intestinal microbiota may cause susceptibility to pathogens that is resolved by progressive bacterial outgrowth and colonization. Succession is central to ecological theory but not widely documented in studies of the vertebrate microbiome. Here, we study succession in the hamster gut after treatment with antibiotics and exposure to Clostridium difficile. C. difficile infection is typically lethal in hamsters, but protection can be conferred with neutralizing antibodies against the A and B toxins. We compare treatment with neutralizing monoclonal antibodies (mAb) to treatment with vancomycin, which prolongs the lives of animals but ultimately fails to protect them from death. We carried out longitudinal deep sequencing analysis and found distinctive waves of succession associated with each form of treatment. Clindamycin sensitization prior to infection was associated with the temporary suppression of the previously dominant Bacteroidales and the fungus Saccinobaculus in favor of Proteobacteria. In mAb-treated animals, C. difficile proliferated before joining Proteobacteria in giving way to re-expanding Bacteroidales and the fungus Wickerhamomyces. However, the Bacteroidales lineages returning by day 7 were different from those that were present initially, and they persisted for the duration of the experiment. Animals treated with vancomycin showed a different set of late-stage lineages that were dominated by Proteobacteria as well as increased disparity between the tissue-associated and luminal cecal communities. The control animals showed no change in their gut microbiota. These data thus suggest different patterns of ecological succession following antibiotic treatment and C. difficile infection.

Indexed as

AnimalsAnti-Bacterial AgentsAntibodies, MonoclonalAntibodies, NeutralizingBacteriaBacterial ProteinsBacterial ToxinsClostridioides difficileCluster AnalysisCricetinaeDNA, BacterialDNA, FungalEcosystemEnterotoxinsFecesFungiAnti-Bacterial AgentsAntibodies, MonoclonalAntibodies, NeutralizingBacterial ProteinsBacterial ToxinsDNA, BacterialDNA, FungalEnterotoxinsRNA, Ribosomal, 16StcdA protein, Clostridium difficiletoxB protein, Clostridium difficile

Identifiers

PMID23071679
PMCPMC3468616
OpenAlexW2093474433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.